| Protocol | Title |
|---|---|
| E1F05 | Phase II Study of Rituximab Given in Conjunction with Standard
Chemotherapy in Primary Central Nervous System (CNS) Lymphoma
Activation Date: 21-dec-2006 Suspended: 24-feb-2010 |
| E3F05 | Phase III Study of Radiation Therapy With or Without Temozolomide for
Symptomatic or Progressive Low-Grade Gliomas
Activation Date: 11-sep-2009 |
| N0574 | Phase III Randomized Trial of the Role of Whole Brain Radiation
Therapy in Addition to Radiosurgery in PAtients with One to Three
Cerebral Metastases
Activation Date: 08-aug-2006 |
| NCCTGN0577 | Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone
versus Radiotherapy with Concomitant and Adjuvant Temozolomide for
Patients with 1p/19q Codeleted Anaplastic Glioma
Activation Date: 22-sep-2009 |
| RTOG0825 | A Phase III Double-Blind Placebo-Controlled Trial of Conventional
Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab
Versus Conventional Concurrent Chemoradiation and Adjuvant
Temozolomide in Patients With Newly Diagnosed Glioblastoma
Activation Date: 22-apr-2009 |
| Protocol | Title |
|---|---|
| 40101 | Cyclophosphamide and Doxorubicin (CA)(4 vs 6 Cycles) Versus
Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Breast Cancer in
Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase
III Randomized Study
Activation Date: 15-may-2002 |
| CALGB40503 | A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of
Endocrine Therapy Alone or Endocrine Therapy plus Bevacizumab (NSC
704865; IND 7921) for Women with Hormone Receptor-Positive Advanced
Breast Cancer
Activation Date: 22-may-2008 |
| E5103 | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide
followed by Paclitaxel with Bevacizumab or Placebo in Patients with
Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Activation Date: 02-nov-2007 |
| I2402 | A Phase III Trial Evaluating the Role of Ovarian Function Suppression
and the Role of Exemestane as Adjuvant Therapies for Premenopausal
Women with Endocrine Responsive Breast Cancer (SOFT)
Activation Date: 04-aug-2003 |
| IBCSG2502 | A Phase III Trial Evaluating the Role of Exemestane Plus GnRH
Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine
Responsive Breast Cancer (TEXT)
Activation Date: 04-aug-2003 |
| N063D | ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation
Study: A Randomised, Multi-centre, Open-label, Phase III Study of
Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination
in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Activation Date: 15-feb-2008 |
| PACT1 | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial
Assigning IndividuaLized Options for Treatment: The TAILORx Trial
Activation Date: 07-apr-2006 |
| S0221 | A Phase III Trial of Continuous Schedule AC + G Vs Q 2 Week Schedule
AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for
12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or
High-Risk Node Negative Breast Cancer
Activation Date: 14-nov-2003 |
| S0230 | Phase II Trial of LHRH Analog Administration During Chemotherapy to
Reduce Ovarian Failure Following Chemotherapy in Early Stage,
Hormone-Receptor Negative Breast Cancer
Activation Date: 06-jan-2005 |
| S0500 | A Randomized Phase III Trial to Test the Strategy of Changing Therapy
versus Maintaining Therapy for Metastatic Breast Cancer Patients who
Have Elevated Circulating Tumor Cell Levels at First Follow Up
Assessment
Activation Date: 01-oct-2006 |
| Protocol | Title |
|---|---|
| C80405 | A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin /
5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the
Combination of Bevacizumab and Cetuximab for Patients with Untreated
Metastatic Adenocarcinoma of the Colon or Rectum
Activation Date: 22-sep-2005 |
| calgb80802 | Phase III Randomized Study of Sorafenib Plus Doxorubicin Vs Sorafenib
in Patients with Advanced Hepatocellular Carcinoma (HCC)
Activation Date: 22-feb-2010 |
| E1208 | A Phase III Randomized, Double-Blind Trial of Chemoembolization with
or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC)
in Patients with and without Vascular Invasion
Activation Date: 28-oct-2009 |
| E3204 | Phase II Study of Preoperative Radiation with Concurrent
Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and
Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab
in Patients with Locally Advanced Rectal Cancer
Activation Date: 25-jul-2006 ECOG Participants(requires Adobe Acrobat) |
| E3205 | Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and
Radiation in Immunocompetent Patients with Anal Carcinoma (Limited
institution participation)
Activation Date: 19-jan-2007 |
| E4203 | Phase II Study of Treatment Selection Based Upon Tumor Thymidylate
Synthase Expression in Previously Untreated Patients with Metastatic
Colorectal Cancer
Activation Date: 14-jul-2005 ECOG Participants(requires Adobe Acrobat) |
| E4206 | A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in
Patients with Low-Grade Neuroendocrine Tumors
Activation Date: 16-sep-2008 ECOG Participants(requires Adobe Acrobat) |
| E5202 | A Randomized Phase III Study Comparing 5-FU, Leucovorin and
Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in
Patients with Stage II Colon Cancer at High Risk for Recurrence to
Determine Prospectively the Prognostic Value of Molecular Markers
Activation Date: 04-aug-2005 |
| NSABPR04 | A Clinical Trial Comparing Preoperative Radiation Therapy and
Capecitabine with or without Oxaliplatin with Preoperative Radiation
Therapy and Continuous Intravenous Infusion of 5-Flourouracil with or
without Oxaliplatin in the Treatment of Patients with Operable
Carcinoma of the Rectum
Activation Date: 23-jul-2004 |
| RTOG 0436 | A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel,
Cisplatin and Radiation for Patients With Esophageal Cancer Who Are
Treated Without Surgery
Activation Date: 08-jul-2008 |
| S0518 | A Phase III Prospective Randomized Comparison of Depot Octreotide
Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC
#704865) in Advanced, Poor Prognosis Carcinoid Patients
Activation Date: 10-dec-2007 |
| S0600 | Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab
(NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line
Therapy for Patients with Metastatic Colorectal Cancer who have
Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Activation Date: 22-jun-2007 |
| Protocol | Title |
|---|---|
| 90202 | A Randomized, Double Blind, Placebo-Controlled Phase III Study of
Early versus Standard Zoledronic Acid to Prevent Skeletal Related
Events in Men with Prostate Cancer Metastatic to Bone
Activation Date: 09-feb-2004 |
| C90203 | A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen
Deprivation Prior to Radical Prostatectomy versus Immediate Radical
Prostatectomy in Patients with High-Risk, Clinically Localized
Prostate Cancer
Activation Date: 15-dec-2006 |
| 90601 | A Randomized Phase III Study of Gemcitabine, Cisplatin, Bevacizumab
or Gemcitabine, Cisplatin, and Placebo in Patients with Advanced
Transitional Cell Carcinoma
Activation Date: 07-aug-2009 |
| E2804 | The BEST Trial: A Randomized Phase II Study of VEGF, RAF kinase and
mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib
and Temsirolimus in Advanced Renal Cell Carcinoma
Activation Date: 14-sep-2007 |
| E2805 | ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal
Carcinoma
Activation Date: 24-apr-2006 |
| E3805 | CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized
Trial for Extensive Disease in Prostate Cancer
Activation Date: 28-jul-2006 |
| E4805 | A Randomized Phase II Study to Determine the Effect of 2 Different
Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell
Carcinoma
Activation Date: 21-dec-2007 ECOG Participants(requires Adobe Acrobat) |
| JPR11 | A Phase III Study of Active Surveillance Therapy Against Radical
Treatment in Patients Diagnosed with Favorable Risk Prostate Cancer
(START) (Limited institution participation)
Activation Date: 11-jun-2008 |
| R0524 | A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab
with Daily Irradiation or Paclitaxel Alone with Daily Irradiation
Following Transurethral Surgery for Non-Cystectomy Candidates with
Muscle-Invasive Bladder Cancer
Activation Date: 09-jan-2007 |
| RTOG 0534 | A Phase III Trial Of Short Term Androgen Deprivation With Pelvic
Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate
Cancer Patients With A Rising PSA After Radical Prostatectomy
Activation Date: 22-feb-2008 |
| S0421 | Phase III Study of Docetaxel and Atrasentan vs. Docetaxel and Placebo
for Patients with Advanced Hormone Refractory Prostate Cancer
Activation Date: 22-aug-2006 |
| Protocol | Title |
|---|---|
| E1305 | A Phase III Randomized Trial of Chemotherapy With or Without
Bevacizumab in Patients with Recurrent or Metastatic Head and Neck
Cancer
Activation Date: 08-aug-2008 |
| Protocol | Title |
|---|---|
| 10403 | An Intergroup Phase II Clinical Trial for Adolescents and Young
Adults with Untreated Acute Lymphoblastic Leukemia (ALL)
Activation Date: 14-may-2008 |
| 10404 | A Genetic, Risk-Stratified Randomized Phase II Study of Four
Fludarabine/Antibody Combinations for Patients with Symptomatic,
Previously Untreated Chronic Lymphocytic Leukemia
Activation Date: 14-may-2008 |
| CALGB10603 | A Phase III Randomized, Double-Blind Study of Induction
(Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine)
Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed
Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia
(AML)
Activation Date: 22-apr-2008 |
| E1902 | A Phase II Study of Reduced Intensity Allogeneic Stem Cell Transplant
for the Treatment of Myelodysplastic Syndromes
Activation Date: 18-may-2005 Suspended: 23-sep-2009 ECOG Participants(requires Adobe Acrobat) |
| E1904 | A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase,
and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults
with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
Activation Date: 29-jun-2006 ECOG Participants(requires Adobe Acrobat) |
| E1905 | A Randomized Phase II Trial of Azacitidine with or without the
Histone Deacetylase Inhibitor Entinostat for the Treatment of
Myelodysplastic Syndrome,Chronic Myelomonocytic Leukemia (Dysplastic
Type), and Acute Myeloid Leukemia with Multilineage Dysplasia
Activation Date: 18-aug-2006 |
| E1906 | A Phase II Randomized Trial of Carboplatin and Topotecan;
Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus,
Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of
Adults with Primary Refractory or Initial Relapse of Acute
Myelogenous Leukemia(AML) (Limited institution participation)
Activation Date: 16-oct-2008 |
| E2903 | Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR)
Followed By Campath-1H For Previously Treated Relapsed or Refractory
Patients With Chronic Lymphocytic Leukemia
Activation Date: 16-dec-2004 ECOG Participants(requires Adobe Acrobat) |
| E2905 | Randomized Phase III Trial Comparing the Frequency of Major Erythroid
Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in
Combination with Epoetin Alfa (Procrit) in Subjects with Low- or
Intermediate-1 Risk MDS and Symptomatic Anemia
Activation Date: 29-jan-2009 |
| E3903 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on
Patients Considered for ECOG Treatment Trials for Leukemia or Related
Hematologic Disorders
Activation Date: 08-jul-2004 ECOG Participants(requires Adobe Acrobat) |
| S0521 | A Randomized Trial of Maintenance Versus Observation For Patients
With Previously Untreated Low and Intermediate Risk Acute Promyelomic
Leukemia (APL), Phase III
Activation Date: 22-jan-2008 |
| S0535 | A Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin
in Patients with Previously Untreated High-Risk Acute Promyelocytic
Leukemia
Activation Date: 23-jun-2008 |
| Protocol | Title |
|---|---|
| CALGB50303 | A Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with
Molecular Profiling in Untreated De Novo Diffuse Large B-Cell
Lymphomas
Activation Date: 23-may-2005 |
| BMTCTN0701 | Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell
Transplantation for Patients with Relapsed Follicular Non-Hodgkin's
Lymphoma Beyond First Complete Response
Activation Date: 23-feb-2009 |
| S0816 | A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin
Lymphoma Using Early Interim FDG-PET Imaging
Activation Date: 08-jul-2009 |
| Protocol | Title |
|---|---|
| E1697 | Phase III Randomized Study of Four Weeks High Dose IFN-A2B in Stage
T2B NO, T3A-B NO, T4A-B NO, and T1-4, N1A, 2A (microscopic) Melanoma
Activation Date: 22-dec-1998 |
| E2602 | A Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with
Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor.
Activation Date: 05-sep-2003 ECOG Participants(requires Adobe Acrobat) |
| E2607 | A Phase II Trial of Dasatinib in Patients with Unresectable Locally
Advanced or Stage IV Mucosal, Acral and Solar Melanomas
Activation Date: 01-may-2009 ECOG Participants(requires Adobe Acrobat) |
| Protocol | Title |
|---|---|
| E1A05 | Randomized Phase III Trial of Consolidation Therapy with
Bortezomib(Velcade)-Lenalidomide (Revlimid)-Dexamethasone (VRD)
versus Bortezomib (Velcade)-Dexamethasone (VD) for Patients with
Multiple Myeloma who have Completed a Dexamethasone Based Induction
Regimen
Activation Date: 06-sep-2007 |
| E1A06 | An Intergroup Phase III Randomized Controlled Trial Comparing
Melphalan, Prednisone and Thalidomide (MPT) versus Melphalan,
Prednisone and Lenalidomide (Revlimid)(MPR) in Newly Diagnosed
Multiple Myeloma Patients who are not Candidates for High Dose
Therapy
Activation Date: 29-feb-2008 |
| E3A05 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on
Patients Considered for Studies of Plasma Cell Disorders
Activation Date: 30-aug-2006 ECOG Participants(requires Adobe Acrobat) |
| S0777 | A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813 and
Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239),
Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in
Patients with Previously Untreated Multiple Myeloma without an Intent
for Immediate Autologous Stem Cell Transplant
Activation Date: 08-apr-2008 |
| Protocol | Title |
|---|---|
| 140503 | A Phase III Randomized Trial of Lobectomy versus Sublobar Resection
for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer
Activation Date: 09-jul-2007 |
| CALGB30610 | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients
with Limited Small Cell Lung Cancer also Receiving Cisplatin and
Etoposide
Activation Date: 21-mar-2008 |
| E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without
Bevacizumab for Patients With Completely Resected Stage IB (>/= 4 cm)
- IIIA Non-Small Cell Lung Cancer (NSCLC)
Activation Date: 01-jun-2007 |
| E1508 | A Randomized Phase II Study of Cisplatin and Etoposide in Combination
with Either Hedgehog Inhibitor GD-0449 or IGF-IR MoAB IMC-A12 for
Patients with Extensive Stage Small Cell Lung Cancer
Activation Date: 16-jul-2009 Suspended: 05-mar-2010 ECOG Participants(requires Adobe Acrobat) |
| E2508 | Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating
Erlotinib in Non-Smoking Patients with (Bevacizumab-eligible and
Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)
Activation Date: 27-jan-2010 ECOG Participants(requires Adobe Acrobat) |
| E3508 | A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab
with or without IMC-A12 in Patients with Advanced Non-Squamous,
Non-Small Cell Lung Cancer
Activation Date: 09-mar-2010 |
| E4508 | Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in
Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small
Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-based
Therapy
Activation Date: 11-sep-2009 ECOG Participants(requires Adobe Acrobat) |
| RTOG 0617 | A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus
High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and
Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients With
Stage IIIA/IIIB Non-Small Cell Lung Cancer
Activation Date: 10-dec-2007 |
| S0424 | Molecular Epidemiology Case-Series Study of Non-Small Cell Lung
Cancer in Smoking and Non-Smoking Women and Men
Activation Date: 01-oct-2005 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 03/11/10